Overview

A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Combination Therapy of T-614 and Methotrexate in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate

Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of T-614 versus placebo when added to ongoing, stable-dose methotrexate therapy in patients with persistently active rheumatoid arthritis
Phase:
Phase 3
Details
Lead Sponsor:
Eisai Co., Ltd.
Collaborators:
FUJIFILM Toyama Chemical Co., Ltd.
Toyama Chemical Co., Ltd.
Treatments:
Methotrexate